肿瘤药学2018，Vol.8Issue(1)：104-107,4.DOI:10.3969/j.issn.2095-1264.2018.01.24
TP方案新辅助化疗对上皮性卵巢癌ERCC1表达的影响及临床疗效分析
The Effect of Taxol and Cisplatin Neoadjuvant Chemotherapy on the ERCC1 Expression and Clinical Efficacy of Patients with Epithelial Ovarian Cancer
杨飏 1莫生娣 1罗嘉 1侯世敏 1徐静1
作者信息
- 1. 湘西自治州人民医院 妇产科,湖南 吉首,416000
- 折叠
摘要
Abstract
Objective To detect the expression level of ERCC1-mRNA in the blood of patients with epithelial ovarian cancer (EOC) and the effect of neoadjuvant chemotherapy on the expression of ERCC1 and its relationship with the clinical efficacy of patients with epithelial ovarian cancer. Methods 35 patients were treated with taxol and cisplatin neoadjuvant combined with cytoreduction surgery and TP chemo-therapy strategy. 40 patients were treated with cytoreduction surgery and TP chemotherapy. The blood ERCC1 mRNA expression patients were detected and its relationship with clinical efficacy was studied. Results There was no significant difference in the relative expression of ERCC1 gene between the two groups before treatment (P>0.05). The relative expression of ERCC1 in the experimental group was (5.9±3.1) after the completion of neoadjuvant chemotherapy, which was significantly higher than that before treatment (P<0.05). The median survival time of the experimental group was (17.6±2.3) months, the median survival time of the control group was (17.1±2.7) months, and there was no significant difference in the two groups (P>0.05). The patients in the two groups were followed up for 12 months after the completion of treatment. The clinical efficacy was analyzed. The effective rate of the experimental group was 51.4%, while the effective rate of the control group was 60.0%, the difference was not statistically significant (P>0.05). Conclusion Neoadjuvant chemotherapy may induce the expres-sion of ERCC1, and the use of neoadjuvant chemotherapy can improve the clinical benefit of cancer patients.关键词
上皮性卵巢癌/ERCC1基因/新辅助化疗Key words
epithelial ovarian cancer/ERCC1/Neoadjuvant chemotherapy分类
医药卫生引用本文复制引用
杨飏,莫生娣,罗嘉,侯世敏,徐静..TP方案新辅助化疗对上皮性卵巢癌ERCC1表达的影响及临床疗效分析[J].肿瘤药学,2018,8(1):104-107,4.
